Diazepam
Brand names: Diazepam, Valium, Valtoco
Part of: Benzodiazepines
At a glance
- Medicare prescriptions, 2024
- 2,213,078
- Medicare drug cost
- $27.3M
- Average cost per prescription
- $12.33
- Clinicians who prescribed it
- 76,679
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
VALTOCO ® is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 25.6%
- Internal Medicine 18.7%
- Nurse Practitioners 12.8%
- Psychiatry 11.1%
- Psychiatric Nurse Practitioners 6.7%
- Physician Assistants 6.6%
- Neurology 3.9%
- Pain Medicine 3.5%
- Physical Medicine & Rehabilitation (PM&R) 1.5%
- General Practice 0.7%
- Urology 0.7%
- ENT (Otolaryngology) 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 12% from 2019 to 2024.
Biggest change by state since 2019
- Delaware +10%
- Idaho −0%
- Utah −2%
- Florida −5%
- Oklahoma −6%
- Puerto Rico (smallest change) −25%
- California (smallest change) −23%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | white round tablet, 9 mm, scored to split in 2 | D 2 |
| 5 mg | yellow round tablet, 9 mm, scored to split in 2 | D 5 |
| 10 mg | blue round tablet, 9 mm, scored to split in 2 | D 10 |
Mylan Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | white round tablet, 8 mm, scored to split in 2 | MYLAN 271 |
| 5 mg | orange round tablet, 8 mm, scored to split in 2 | MYLAN 345 |
| 10 mg | green round tablet, 8 mm, scored to split in 2 | MYLAN 477 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $1.4M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Neurelis, Inc. $1.4M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.